In the second quarter of 2017, biopharma companies brought in a total of $13.4 billion in financing, nearly doubling the first quarter's $6.8 billion aggregate. Initial public offerings boasted the highest dollar value, reaching $4.7 billion, or over one-third of the total. Interestingly, this financing type had one of the lowest volume counts – 18 – during the quarter, indicating the average IPO transaction was quite high. (See Exhibit 1.)
Biopharma Quarterly Deal-Making Statistics, Q2 2017
A look at financing, M&A and alliance activity April–June 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.

More from Deal-Making
More from In Vivo
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.